RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease
Compared to tacrolimus, SANPs and CNPs demonstrated superior therapeutic efficacy and a reduced incidence of adverse effects in the treatment of diabetic nephropathy.
Authors
- Zhaojie Liu (ORCID: https://orcid.org/0000-0002-2212-3672)
- Caihong Zeng (ORCID: https://orcid.org/0000-0002-3816-5164)
- Weisong Qin
- Ziyue Wang (ORCID: https://orcid.org/0000-0002-4311-8653)
- Qinger Wang
- Zhaochen Guo (ORCID: https://orcid.org/0000-0003-3135-6213)
- Zhihong Liu (ORCID: https://orcid.org/0000-0003-1500-9342)
- Feng Xu (ORCID: https://orcid.org/0000-0002-1538-2908)
- Hao Bao (ORCID: https://orcid.org/0000-0002-8904-811X)
- Zige Chen
- Shaohui Gao
Institutions
- Nanjing General Hospital of Nanjing Military Command (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1186/s12951-025-03108-4
- Citations
- 6
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 8.58